NCT04487574已完成3 期
A Multicenter, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of XC221, Tablets, 100 mg in Patients With COVID-19
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 118
- 试验地点
- 5
- 主要终点
- Patient rate with a transition to category 3 or lower according to the WHO scale by Day 14 after the beginning of drug administration.
研究概览
简要总结
The innovative drug XC221 100 mg tablet is designed for the treatment of COVID-19 (SARS-CoV-2 infection). A multicenter, adaptive, randomized, double-blind, placebo-controlled Phase III clinical study is aimed to assess the efficacy and safety of XC221 100 mg tablet, in COVID-19 patients during a 14-day treatment.
The primary objective of the study is to demonstrate the efficacy of XC221 100 mg tablet (200 mg daily dose) in achieving clinical improvement of COVID-19 symptoms.
The secondary objective of the study is to evaluate the safety of XC221 100 mg tablet (200 mg daily dose) in COVID-19 patients.
详细描述
11 Russian centers will participate in this study. The trail will consist of three periods: screening (duration not more than 1 day, it may coincide with the randomization visit and beginning of drug administration), treatment period (14 days) and follow-up period (14 ± 1 days after completion of treatment with XC221 / Placebo). The duration of participation in the study for each patient will be no more than 30 days.
118 eligible patients with confirmed COVID-19 will be randomized into two groups (Group A and Group B) in a 1:1 ratio: Group A - XC221 200 mg daily (59 patients); Group В - Placebo (59 patients).
During the treatment period (14 days), 1 tablet of XC221 / Placebo will be administered 2 times a day in addition to the standard of care (SoC) for COVID-19 according to The Temporary guidelines for the prevention, diagnosis and treatment of SARS-CoV-2 infection of the Ministry of Health of the Russian Federation (the MoH Temporary Guidelines). The follow-up period will last for 14 days.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
盲法说明
Tablets identical in terms of composition, appearance and labeling to XC221 tablets, but without active substance will be used as Placebo.
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed Informed Consent Form.
- •Patients of both sexes aged 18 to 75 years inclusive.
- •Diagnosed COVID-19 based on:
- •positive laboratory tests confirming the SARS-CoV-2 presence, performed no earlier than 14 days before hospitalization. It is allowed to determine the SARS-CoV-2 by the PCR or by another method according to the MoH Temporary Guidelines; and / or
- •bilateral alterations in lungs, typical for COVID-19, according to CT scan of the chest.
- •Patients with moderate or severe form of disease (t > 38.0°C; respiratory rate (RR) >22 / min; Sp02 <95%) not requiring non-invasive / invasive ventilation and / or high-flow oxygenation (HFNT), and / or extracorporeal membrane oxygenation (EMO) at the time of screening and randomization (based on the MoH Temporary Guidelines).
- •Patients requiring oxygen therapy (oxygenation through a nasal cannula, a simple facemask or other similar oxygen delivery device) with a category "4" according to the WHO scale.
- •Time from hospitalization to the first drug administration should not exceed 48 hours. This item is to be assessed only when re-evaluating the inclusion / exclusion criteria at the Randomization visit and treatment initiation.
- •Disease duration is no more than 7 full days since the moment of appearing one or more of the symptoms below until the first dose of the drug administration:
- •temperature increase;
- •dry cough or cough with little phlegm;
- •shortness of breath;
- •feeling of congestion in the chest;
- •reduced sense of smell and / or taste.
- •For women only: negative pregnancy test result. Pregnancy testing is not required for women of not childbearing potential (WONCBP): women who are in menopause (defined as an absence of menstruation for at least 2 years or more), or women who undergone surgical sterilization (hysterectomy, bilateral oophorectomy, tubal ligation), or women with a clinical diagnosis of "infertility". The presence of surgical sterilization and infertility should be confirmed by patient's claim or by relevant document confirming this condition.
- •Consent to use reliable method of contraception throughout the study period.
- •Patients who are able to understand and comply with treatment and procedures during the study.
排除标准
- •Known or suspected hypersensitivity to the active substance or to excipients of the drug XC221 or placebo
- •Known or suspected hypersensitivity to standard therapy drugs specified in The MoH Temporary Guidelines.
- •Lactase deficiency, lactose intolerance, glucose-galactose malabsorption.
- •Presence or suspicion of oncological diseases by the day of criteria assessment or in medical history (within the last 2 years).
- •Presence of autoimmune diseases by the day of criteria assessment or in medical history.
- •Neutropenia (0.5 * 10^9 /l).
- •Exceeding the upper limit of normal for ALT and AST by 5 times or more.
- •Thrombocytopenia 50000 / mm^
- •Presence of serious lung diseases, including, but not limited to the following diseases: moderate and severe bronchial asthma, severe and extremely severe COPD, interstitial lung disease, pulmonary hypertension, pulmonary fibrosis, surgical interventions on the lungs, tuberculosis (including suspicion of tuberculosis based on the results of CT examination at screening).
- •Patients with type 1 diabetes mellitus and / or decompensated type 2 diabetes mellitus.
- •Heart failure, NYHA functional class III - IV.
- •Chronic liver failure stage II (decompensated) and higher.
- •The need of renal replacement therapy at the time of inclusion of the patient.
- •Organ transplantation in medical history.
- •Medical history of epilepsy or the need for anticonvulsant therapy.
- •Major depressive disorder, anxiety, other mental disorders requiring medical correction.
- •Acute cerebrovascular accident, stroke or transient ischemic attack within 90 days before screening.
- •Administration of any antiviral and / or immunomodulatory drugs after the manifestation of COVID-19, with the exception of those specified in the MoH Temporary Guidelines.
- •Any immunosuppressive therapy (including tocilizumab / sarilumab) within 90 days prior to randomization, or the need of immunosuppressive therapy at the time of randomization.
- •Administration of systemic glucocorticosteroids within 90 days prior to randomization, or the need of systemic glucocorticosteroids at the time of randomization.
- •Administration of vaccines against viral infections within 90 days prior to randomization.
- •Patients receiving other experimental drugs, drugs not approved in the Russian Federation, or participating in other clinical trials within 30 days before screening.
- •Patients abusing alcohol or psychotropic drugs and other drugs by the day of criteria assessment or during the last year.
- •Patients with other serious, unstable, or clinically significant medical or psychological conditions that, in the opinion of the investigator, may preclude the patient's participation in the study.
- •Expected death within 48 hours after randomization.
- •Expected hospital discharge within 48 hours of randomization.
研究组 & 干预措施
XC221
Experimental
XC221 100 mg orally.
1 tablet of XC221 100 mg 2 times a day during 14 days of treatment period.
干预措施: XC221 (Drug)
Placebo
Placebo Comparator
Placebo orally.
1 tablet of Placebo 2 times a day during 14 days of treatment period
干预措施: Placebo (Drug)
结局指标
主要结局
Patient rate with a transition to category 3 or lower according to the WHO scale by Day 14 after the beginning of drug administration.
时间窗: Day 1 - Day 14
The scale of the patient's clinical condition, proposed by the WHO, will be used to assess the severity of patient general condition. Ranges for patient's clinical condition: 0 points (no infection) - 8 points (death).
次要结局
- The total duration of invasive ventilation of lungs by the last day of hospitalization.(Day 1 - Day 28)
- Time till clinical improvement, which is described by presence of all of the following factors during 48 hours in a row.(Day 1 - Day 28)
- Patient rate with clinical improvement by day 2-28. Presence of all of the following factors during 48 hours in a row.(Day 1 - Day 28)
- Patient rate with ARDS during hospitalization.(Day 1 - Day 28)
- Patient rate with a negative test result for SARS-CoV-2 by Day 7±1, 15±1, 21 ±1 and 28 ± 1.(Day 1 - Day 28)
- Duration of hospitalization.(Day 1 - Day 28)
- Patient rate transferred to the intensive care unit (ICU) during hospitalization.(Day 1 - Day 28)
- Duration of ICU stay.(Day 1 - Day 28)
- Presence of a fatal outcome.(Day 1 - Day 28)
- Patient rate requiring oxygen therapy by Day 2-28.(Day 1 - Day 28)
- Patient rate requiring high-flow oxygen therapy by Day 2-28.(Day 1 - Day 28)
- Patient rate requiring non-invasive ventilation by Day 2-28.(Day 1 - Day 28)
- Patient rate requiring invasive ventilation by Day 2-28.(Day 1 - Day 28)
- Patient rate requiring extracorporeal membrane oxygenation (EMO) by Day 2-28.(Day 1 - Day 28)
- The total duration of oxygen therapy by the last day of hospitalization.(Day 1 - Day 28)
- The total duration of high-flow oxygen therapy by the last day of hospitalization.(Day 1 - Day 28)
- The total duration of non-invasive ventilation by the last day of hospitalization.(Day 1 - Day 28)
- The total duration of EMO by the last day of hospitalization.(Day 1 - Day 28)
- Average time to reach SpO2 ≥ 95%.(Day 1 - Day 28)
- Patient rate with RR < 22 / min by Day 2-28.(Day 1 - Day 28)
- Average alteration in RR by Day 2-28 from baseline.(Day 1 - Day 28)
- Average time to reach RR ≤ 22 / min.(Day 1 - Day 28)
- Patient rate with body temperature < 37.5°C by Day 2-28.(Day 1 - Day 28)
- Average alteration in body temperature by Day 2-28 from baseline.(Day 1 - Day 28)
- Average time to reach CT-1 according to CT data.(Day 1 - Day 28)
- Patient rate with Sp02 > 95% by Day 2-28.(Day 1 - Day 28)
- Average alteration of Sp02 by Day 2-28 from baseline.(Day 1 - Day 28)
- Patient rate with CT-1 according to CT data by Day 2-28.(Day 1 - Day 28)
- Average alteration in CT data by 1 point in terms of severity (CT-1, CT-2, CT-3, CT-4) by Day 7, 10, 15, 18, 21 and 28 compared to the baseline value.(Day 1 - Day 28)
- Patient rate with a score < 2 according to the Daytime and Nighttime Cough Scale by Day 2-28.(Day 1 - Day 28)
- Mean change in Daytime and Nighttime Cough scores by Day 2-28 from baseline.(Day 1 - Day 28)
- Average time to reach < 2 points when assessed according to the Daytime and Nighttime Cough Scale.(Day 1 - Day 28)
- Patient rate with a score < 1 for each symptom (general fatigue, chest congestion, sore throat, decreased sense of smell and taste, nasal congestion) according to a 4-point scale by Day 2-28.(Day 1 - Day 28)
- Average time until the patient reaches a body temperature of ≤37.5°C.(Day 1 - Day 28)
- Patient rate with a transition decrease to category 3 or lower according to the WHO scale by Day 2-13 and Day 15-28.(Day 1 - Day 28)
- Average change in score for each symptom (general fatigue, chest congestion, sore throat, decreased sense of smell and taste, nasal congestion) according to a 4-point scale by Day 2-28 from baseline.(Day 1 - Day 28)
- Mean WHO grade change by Day 2-28 from baseline.(Day 1 - Day 28)
- Average change in NEWS score by Day 2-28 from baseline.(Day 1 - Day 28)
- Average time to reach a score of < 1 for each symptom (general fatigue, feeling of congestion in the chest, sore throat, decreased sense of smell and taste, nasal congestion) according to a 4-point scale.(Day 1 - Day 28)
- Average time to reach the 3rd category or below according to the WHO scale.(Day 1 - Day 28)
- Patient rate with a NEWS score < 2 by Day 2-28.(Day 1 - Day 28)
- Average time to reach a NEWS score ≤ 2.(Day 1 - Day 28)
研究者
研究点 (5)
Loading locations...
相似试验
已完成
3 期
A Study to Assess the Efficacy and Safety of XC221 in Patients With Mild COVID-19Sars-CoV-2 InfectionNCT04940182RSV Therapeutics LLC274
已完成
2 期
Study to Assess Efficacy and Safety of XC221 200 mg in the Treatment of Influenza or Other ARVIAcute Respiratory Viral InfectionsInfluenzaNCT03830905PHARMENTERPRISES LLC120
已完成
3 期
A Study to Evaluate the Safety and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory InfectionsRespiratory Viral InfectionInfluenzaNCT05544916Valenta Pharm JSC260
暂停
2 期
Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac®) Vaccine in Healthy Adults in TurkeyCOVID-19NCT05150496Sinovac Research and Development Co., Ltd.640
已完成
1 期
A Study of FB2001 for Inhalation in Healthy Chinese AdultsCOVID-19 PandemicNCT05583812Frontier Biotechnologies Inc.32